Anti-hEpCAM-CD3
-
Cat.code:
bimab-ecamcd3-01
- Documents
ABOUT
Monoclonal scFv antibody against human EpCAM and human CD3
Anti-hEpCAM-CD3 is a bispecific antibody that recognizes two human cell markers: human epithelial cell adhesion molecule (hEpCAM) and hCD3. It features solitomab's single-chain variable fragments (scFv) joined by a glycine-serine linker and a hexahistidine-tag (His6).
Solitomab was developed for the treatment of relapsed/refractory EpCAM-positive solid tumors [1]. By binding to hCD3 and hEpCAM, this dual-targeting antibody engages unstimulated T cells to proliferate and subsequently trigger T cell-mediated lysis of hEpCAM-positive cells (see figure).
Key features
- Reacts with human EpCAM and human CD3
- ScFv of clinical relevant bispecific mAb solitomab
- Hexahistidine (His6) tag
- Provided azide-free
- Each lot is functionally tested
Applications
- Adjustment studies of cancer cell contact-dependent killing
- Improving T cell activation
1. Kebenko M, et al., 2018. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 7(8):e1450710
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
CD3, EpCAM
Human
Sodium phosphate buffer, saccharose
Negative (tested using EndotoxDetect™ assay)
Cellular assays, ELISA, flow cytometry
Each lot is validated by flow cytometry.
CONTENTS
Contents
-
Product:Anti-hEpCAM-CD3
-
Cat code:bimab-ecamcd3-01
-
Quantity:10 µg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
EpCAM
The human epithelial cell adhesion molecule (EpCAM, CD326, Trop1) is a transmembrane, 40 kDa glycoprotein highly abundant in almost all human carcinomas, including colon, prostate, ovarian, or breast cancer [1]. In healthy tissue, EpCAM expression is generally low [1-2]. In cancer, EpCAM overexpression is responsible for tumor proliferation, invasion, and migration and is often correlated with a poor prognosis [1]. Thus, EpCAM represents an attractive therapeutic target. The number of EpCAM-positive cancers with limited therapeutic options at the advanced stage formed the rationale for developing the EpCAM/CD3 BiTE® antibody solitomab (MT110, AMG 110) [1].
CD3
The cluster of differentiation 3 (CD3, formerly named T3) is a multimeric protein complex consisting of four polypeptides (CD3ε, CD3γ, CD3δ, and CD3ζ) that assemble as three dimers (εγ, εδ, and ζζ) [4]. It is a marker of T cells, which recognizes and participates in the elimination of infected cells and tumor cells through the interaction between the TCR (T cell receptor) on T cells and the MHC-peptide complex on antigen-presenting cells [4-5]. Because of its short cytoplasmic tail, the TCR lacks the ability to signal and requires non-covalent association with the CD3. Upon antigen recognition, T cells' TCR/CD3 complex triggers downstream intracellular signaling and activates T cell cells [4].
References:
1. Brischwein K, et al., 2006. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 43(8):1129-43.
2. Kebenko M, et al., 2018. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 7(8):e1450710.
3. Chetty R. & Gatter K., 1994. CD3: structure, function, and role of immunostaining in clinical practice. J. Pathol. 173(4):303-307.
4. Smith-Garvin J.E. et al., 2009. T Cell Activation. Ann. Rev. Immunol. 27:591-619.3.
Illustration on this page were created with BioRender.com.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
